Amongst the synthesized compounds, the best rounding up activity was obtained with compounds 11 and 19 (R 1 = R 2 = R 3 = R 6 = OCH 3 , R 4 = R 5 = H, R 7 = OH) with concentrations of 0.13 and 0.2 µM, respectively.
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Graphical abstract
Introduction
Tumor vasculature is an attractive target for cancer therapy because solid tumors require blood vessels to grow and metastasize [1] [2] [3] [4] . This requirement for neovascularization to allow tumors to grow beyond a certain threshold size drew attention to the potential therapeutic agents that may act on angiogenesis which occurs in several steps of the cancer process and offers several targets for intervention [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] .
Tumor vascularization is the result of pro-angiogenic factors and inhibitors and involves the interaction between endothelial cells and extracellular matrix. Various approaches have been developed to improve tumor control through the vascular targeting agents which can be divided into antiangiogenic and vascular-disrupting agents (VDAs) [11] [12] [13] [14] .
Considering the VDAs [15, 16] , the best active compounds that have been found to date are acting on tubulin polymerization. In this context, the molecule that emerged as one of the most potent is combretastatin A4 (CA4 1) which is a cis-stilbene derivative that was selected among seventeen combretastatin compounds originally isolated from the South African bushwillow tree
Combretum caffrum Kuntze (Combretaceae) by Pettit and co-workers [17] [18] [19] . 
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4 inhibition and/or cytotoxicity. To our knowledge, only one report [37] deals with triazoles having vicinal benzyl and phenyl substituents (in the relative 1,5-positions) designed in order to confer to the molecule a higher degree of conformational freedom.
In the context of hitherto unknown 1,2,3-triazoles disubstituted in the 4-and 5-positions by one aryl group and one benzyl substituent, the present study was undertaken to provide information on the biological activities of these compounds. We report here that several compounds of this series present interesting biological activities in the nanomolar or low micromolar range, in terms of rounding up of endothelial cells, inhibition of tubulin polymerization, and cytotoxicity on cancer cells. In silico docking studies of 11 and 19 within the active site of tubulin were also carried out and we also performed a preliminary in vivo evaluation of compounds 11 and 19 which revealed a modest anticancer activity in mice bearing colon 26 carcinoma tumors.
Results and Discussion
Chemistry
The title compounds were prepared starting from 1,3-diaryl-2-nitroprop-1-enes (6) (7) (8) (9) (10) (11) (12) obtained according to a procedure already described by one of us [43] from appropriate arylaldehydes and some 2-aryl-1-nitroethanes (4 or 5) by refluxing in toluene in the presence of dimethylammonium chloride and a small amount of potassium fluoride. The required nitro derivatives 4 and 5 were synthesized by a two-step procedure starting from suitable benzaldehydes via the corresponding 2-aryl-1-nitroethenes (2 or 3, respectively), as depicted in Scheme 1. In a similar way, the indole derivative 21 has been prepared in 93% yield from the already known nitroethene 13 previously synthesized according to reference [43] 
Biological activities
To evaluate the potential antivascular activity of the new cis-constrained analogues of 1, we first assessed their rounding up activity on endothelial cells, which is considered to be predictive of potential in vivo antivascular activity [45] . The compounds were also tested for their inhibition of tubulin polymerization and their cytotoxic activity on the murine B16 melanoma cell line. Table 1 presents the rounding up activity data for the synthesized combretastatin analogues from the most active to the less active compounds. Compared to the reference compound (1) which could elicit a rounding up of endothelial cells at very low concentrations (6 nM), seven compounds of our series showed interesting rounding up activity below 1 µM for a 2 hour exposure time (19, 
Morphological activity
The compound concentrations needed to inhibit tubulin polymerization by 50% are also shown in Table 1 . We observed that the best compounds for tubulin activity were also the ones that could elicit a rounding up of endothelial cells at low concentrations. It is noteworthy that a very good linear correlation exists between the inhibition of tubulin polymerization and the morphological activity (rounding up) on endothelial cells for the most active compounds presenting morphological activity at concentrations of less than 10 µM (Figure 2 ).
Cytotoxicity
Finally our new combretastatin analogues were also evaluated for their cytotoxicity on the B16 melanoma cell line. For this biological activity, the correlation with rounding up activity was less evident. With the exception of compounds 22, 14 and 18, which appear to be outliers, a relative good correlation was nonetheless observed between cytotoxicity and rounding up activity for the best morphologically active compounds (<10 µM).
Structure-activity relationships
Beside the well-known requirement of the 3,4,5-trimethoxyphenyl group for optimal biological activity of combretastatin analogues [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] , we also noted the following interesting 11 to 8 or 23 and 19 to 16) or by a 3-indolyl (compare 6 to 13 and 14 to 21) were found unfavorable to biological activities.
Finally, with the exception of the couple 11/19 where the measured biological activities are very close, the comparison between the nitroalkene series (6-13) and the triazole compounds (14) (15) (16) (17) (18) (19) (20) (21) (22) demonstrates that the nitroalkenes 6-13, having a higher degree of conformational freedom, are more active than their corresponding triazole derivatives.
Considering the relatively good in vitro activities of compounds 11 and 19 in terms of cytotoxicity, rounding up of endothelial cells and inhibition of tubulin polymerization, the putative mechanism of action of these compounds is probably close to that of CA4.
Molecular modeling
In order to compare the putative binding mode of our cis-constrained analogues of CA4 and combretastatin itself, docking studies were carried out by using the reported high-resolution crystal structure of the tubulin-DAMA-colchicine(CN-2) complex (PDB ID: 1SA0) [46] as it was done on other heterocyclic analogues of CA4 [47] . The colchicine site, well described in two recent reviews [48, 49] , is a deep pocket located at the α−β interface of tubulin heterodimers. Massaroti et al. [49] identified three zones of interaction reproduced in Figure 3 . The trimethoxyphenyl ring (TMP or A ring) of CN-2 lies in a hydrophobic pocket of zone 2 while the other side of the molecule (C ring) interacts in zone 1 by van der Waals contacts. Furthermore two residues are highlighted as they are often involved in hydrogen bond interactions with ligands: Cys241 β and Val181 α. It should be noted that the residue numbering system we used is derived from the crystal structure [46] . Docking simulations were performed with GOLD software version 5.1 [50] (see docking protocol for more details). Our protocol was validated by its ability to reproduce the crystal complex structure CN-2 / tubulin by docking the ligand extracted from the complex.
Superimposition, not shown, of our best docked pose on the crystal structure gave an RMSD deviation, based on heavy atoms, of 0.92 Å. The C ring is involved in hydrogen bond with Val181 α. The TMP ring is at a good distance of Cys241 β to be involved in hydrogen bond, but the polar hydrogen atom of cystein is not properly directed to the methoxy oxygen atoms of CN-2. To conclude, we observed the non-coplanar cisoid arrangement of the two aromatic rings, highlighted on Figure 3 , of CA4 and its analogues. This arrangement is described as essential for the biological activity [51] , but it is not sufficient because the loss of some hydrogen bonds and the absence of new ones could explain the lower biological activity than the one observed with CA4.
Evaluation of antitumor activity in colon 26-bearing mice
Based on their good in vitro biological activities, compounds 11 and 19 were selected for further in vivo testing in colon 26 tumor bearing mice. The colon 26 tumor was chosen because this model is responsive to antivascular agents [52] . 
Conclusion
We have, for the first time to our knowledge, synthesized new 1,2,3-triazoles disubstituted in 4-and 5-positions by one benzyl and one aryl groups. We also evaluated these new compounds for potential antivascular and anticancer activities and found that several compounds presented interesting biological activities, e.g., rounding up of endothelial cells (at concentrations in the submicromolar range), inhibition of tubulin polymerization and cytotoxicity on B16 cancer cells (at concentrations in the low micromolar range). In silico docking studies of 11 and 19 within the active site of tubulin were also carried out in order to rationalize the inhibitory properties of these compounds and further understand their inhibition mechanism. In addition, the evaluation of compounds 11 and 19 in tumor bearing mice indicated modest in vivo anticancer activity.
Experimental protocols
Synthesis
Melting points were measured on a Köfler hot stage apparatus and are uncorrected. Mass spectra were recorded on a Waters ZQ 2000 system using electrospray ionization (ESI) or on a Waters LCT apparatus for High-resolution mass spectra (HRMS -ESI). Infrared spectra were obtained using an FT-IR Perkin-Elmer spectrometer as chloroform solutions or KBr discs. NMR spectra were recorded with a Bruker ACP 300 spectrometer at 300 MHz for 1 H NMR and 75 MHz Merck Silica gel (230-400 Mesh ASTM) was used for column chromatography. Methanol and M A N U S C R I P T
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11 To a solution of the corresponding arylaldehyde in toluene were added nitromethane (11 equivalents), dimethylamine hydrochloride (4 equivalents) and potassium fluoride (0.15 equivalents). The flask was equipped with a Dean-Stark and the mixture was heated at reflux temperature until the disappearance of the arylaldehyde (usually noted after a reaction time of 4-5 hours). After being cooled at room temperature, the reaction mixture was evaporated under vacuum to eliminate the toluene, then diluted with water and extracted by CH 2 Cl 2 (3x). In some cases, a filtration over Celite surface was required in order to eliminate excess reagent or reaction residues prior to extraction. The organic phase was then washed with water, dried over MgSO 4 , filtered and concentrated under vacuum. Crude product was purified by chromatography on silica gel in order to afford the desired compound.
2-(3-Hydroxy-4-methoxyophenyl)-1-nitroethene (2).
General procedure 4.1.1. was applied to iso-vanillin (3-hydroxy-4-methoxybenzaldehyde) 
To a flask containing the corresponding 2-aryl-1-nitroethene were added silica gel (2 grams per mmol of starting material), and 1.5 mL of 2-propanol and 8 mL of chloroform per gram of silica gel [53] . To this mixture were added 4 mmol of NaBH 4 per mmol of starting material in small amounts and the resulting mixture was allowed to stir at room temperature until the complete disappearance of the 2-aryl-1-nitroethene (usually noted after a reaction time of about 30 minutes).
The reaction mixture was quenched with an aqueous solution of 0.1 N HCl, filtered to eliminate the silica gel and evaporated under vacuum to eliminate 2-propanol and chloroform. The resulting aqueous mixture was then extracted by CH 2 Cl 2 (3x). The organic phase was dried over MgSO 4 , filtered and concentrated under vacuum. Crude product was purified by chromatography on silica gel in order to afford the desired compound. To a solution of the corresponding 2-aryl-1-nitroethane in xylene were added dimethylamine hydrochloride (2 equivalents), potassium fluoride (0.2 equivalents) and the appropriate arylaldehyde
(1 equivalent). The flask was equipped with a Dean-Stark and the mixture was heated at reflux temperature until the disappearance of the arylaldehyde (usually noted after a reaction time of 24 hours). After being cooled at room temperature, the reaction mixture was evaporated under vacuum to eliminate the xylene, then diluted with water and extracted by CH 2 Cl 2 (3x). The organic phase was then washed with water, dried over MgSO 4 , filtered and concentrated under vacuum. Crude product was purified by chromatography on silica gel in order to afford the desired compound [43] . Compounds 7, 8, 11, 12, 23, 24 , and 25 are already described in ref [43] .
3-(3-Hydroxy-4-methoxyphenyl)-1-(3,4,5-trimethoxyphenyl)-2-nitropropene (6).
General procedure 4.1. 
1-(4-Methoxy-3-nitrophenyl)-3-(3,4,5-trimethoxyphenyl)-2-nitropropene (9).
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1-(3-Fluoro-4-methoxyphenyl)-3-(3,4,5-trimethoxyphenyl)-2-nitropropene (10).
General procedure 4. 
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15 To a solution of the corresponding benzylphenylnitroethene in DMSO (minimum volume: approximately 10 mL for 3 mmol) was added NaN 3 (2 equivalents) [42] . The resulting mixture, which acquired a dark red color right after the addition, was allowed to stir at 85 ºC under argon atmosphere until complete conversion of the starting material (usually noted after a reaction time of 15 hours). After being cooled at room temperature, the reaction mixture was diluted with water and then extracted by CH 2 Cl 2 (4x). The organic phase was dried over MgSO 4 , filtered and concentrated under vacuum. Crude product was purified by chromatography on silica gel. In order to eliminate remaining DMSO, the evaporated fractions containing the desired compound were dissolved in ether and washed with water (3x), dried over MgSO 4 , filtered and then concentrated under reduced pressure.
4-(3-Hydroxy-4-methoxybenzyl)-5-(3,4,5-trimethoxyphenyl)-1,2,3-triazole (14).
General procedure 4.1.4. was applied to 6 (1.13 g, 3.0 mmol) with a reaction time of 12 h. 
5-(4-Methoxy-3-nitrophenyl)-4-(3,4,5-trimethoxybenzyl)-1,2,3-triazole (17).
General procedure 4.1.4. was applied to 9 (1.68 g, 4.15 mmol) with a reaction time of 6 h.
The crude product was purified by chromatography on silica gel, using a gradient of MeOH in C, C-4"), 153.5 (C x 3, C-3', C-4', C-5') ; IR (NaCl): υ' 3017 (NH), 1592 (C=C), 1508 
Biological evaluation procedures
Endothelial cell morphology.
To assess the effects of the compounds on the morphology of endothelial cells, we used the EAhy 926 endothelial cell line which is derived from the fusion of human umbilical vein endothelial cells (HUVEC) with the permanent human cell line A549 [55] . The EAhy 926 cell line is considered as one of the best immortalized HUVEC cell lines because these cells express most of the biochemical markers of parental HUVEC EAhy 926 cells [56] . EAhy 926 cells were grown in DMEM containing 2 mM L-glutamine, 10% fetal bovine serum, 100 U/mL penicillin and 100 µg/mL streptomycin (37°C, 5% CO 2 ). Exponentially growing EAhy 926 cells were plated onto 96 well plates at 5000 cells/100 µL/well. Twenty-four hours after plating, the medium was aspirated, and 100 µL of medium containing the test compound was added to the well containing the cells (in triplicate) and incubated for 2 h (37°C, 5% CO 2 ). The highest concentration used was 100 µM 
Inhibition of tubulin polymerization.
Tubulin microtubule assembly in microtubules was carried out using the fluorescent dye DAPI (4',6-diamidino-2-phenylindole) [57] in a 96-well plate format as described [58, 59] . The standard assay was performed as follows: wells were charged with tubulin (Cytoskeleton, 97% pure, final concentration 1 mg/ml) in PME buffer (100 mM PIPES (1,4-piperazinebis(ethanesulfonic acid); 1 mM MgSO 4 ; 2 mM EGTA) with 10 µM DAPI and varying concentrations of the test compounds using colchicine at 30 µM as an internal positive control. The final concentrations used for the test compounds were started at 30 µM and diluted in 3-fold decrements thereafter until no inhibition was observed. Triplicate wells were run for each concentration. After a preincubation of 45 min at room temperature, 5 µl of 1 mM GTP was added to each well to initiate tubulin polymerization, and the plate was then transferred to a thermostated Victor plate reader at 37 °C for an additional 2 h. 
Cytotoxicity assay.
Murine B16 melanoma cells were grown in DMEM medium containing 2 mM L-glutamine, 10% foetal bovine serum, 100 U/mL penicillin and 100 µg/mL streptomycin (37°C, 5% CO 2 ). All compounds were initially dissolved in DMSO at a stock concentration of 2.5 mg/mL and were further diluted in cell culture medium. Exponentially growing cells were plated onto 96-well plates at 5000 cells per well in 100 µl of culture medium. Twenty-four h after plating, 100 µl of medium containing the compound at final concentrations ranging from 0.01 to 100 µM were added to the wells (in triplicate) containing the cells, and incubated for 48 h at 37 °C and 5% CO 2 . After the 48 h exposure period to the test compounds, cell viability was assayed using the MTT test [60] and absorbance was read at 562 nm in a microplate reader (BioKinetics Reader, EL340). Appropriate 
Docking protocol
Our previous docking work on analogues of Combretastatin A4 [47] implied GOLD (Genetic Optimisation for Ligand Docking), so we performed our study with this software in its new version [50] .
Ligands preparation
Three compounds, CA4, 11 and 19 were initially built within MarvinSketch 5.8.0 from Chemaxon
[61] next submitted to Corina [62] , a 3D structure generator. Obtained 3D conformations were next submitted to Ligprep from the Schrödinger software suite [63] in order to generate tautomers forms.
Regarding a pH=7.0 +/-2.0 three forms were found for 19 where H atom can be bound to the three N atoms of the triazole ring. Due to the high level of flexibility of the previously structures conformational analyses, according to the OPLS2005 force field [64] , were computed and the lowest energy conformations were kept as input for the docking stage.
Protein preparation
3D structure of tubulin was retrieved from the Protein Data Bank (http://www.rcsb.org, PDB ID: 1SA0) [46] . Subunits C, D and E were removed. Only subunits A, B, corresponding to the colchicine binding site, and small molecules DAMA-colchicine (CN2), GTP and Mg 2+ ion in this site were conserved.
Molecular docking
Docking runs were performed with an exploration of the conformational space of ligands more important than with default parameters in that sense that 100 conformations were kept for each ligand and early termination process (run will stop after 3 conformations found within an RMSD of 1.5 Å) was disabled. Goldscore was chosen again as our fitness scoring function.
Antitumor evaluation in mice.
Female BALB/cJRj mice (average weight, 18 g) obtained from Janvier (Le Genest St Isle, France)
were supplied food and water ad libitum. Colon 26 tumor fragments (30 to 60 mg) were implanted bilaterally in the axillary region by subcutaneous injection on day 0 with a 12 gauge trocar [65] .
Bilateral implants were used to insure a more uniform tumor burden per mouse. The methods of protocol design, chemotherapy techniques, and data analysis have been presented in detail M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 22 elsewhere [66, 67] . Briefly, the animals were pooled before distribution to the various treatment and control groups (5 mice per group) and preliminary experiments in non tumored animals allowed to determine the maximum tolerated dose which was 150 mg/kg for 11 and 100 mg/kg for 19, when administered intraperitoneally for two weeks on days 3-7 and 10-14 after tumor implantation (day 0). Compounds were freshly prepared daily in saline containing 5% DMSO and 5% polysorbate 80 and injected intraperitoneally in a volume of 0. 
